Gemcitabine plus docetaxel: A new treatment option for anthracycline pretreated metastatic breast cancer patients?

Cancer Treatment Reviews

Volumn 31, Issue SUPPL. 4, 2005, Pages

  Levy, C ^a   Fumoleau, P ^b  

^a CENTRE FRANÇOIS BACLESSE   (France)

^b CENTRE GEORGES FRANÇOIS LECLERC   (France)

Author keywords

Capecitabine; Combination therapy; Docetaxel; Gemcitabine; Metastatic breast cancer; Progression free survival; Tolerability

Indexed keywords

ANTHRACYCLINE DERIVATIVE; ANTINEOPLASTIC ANTIMETABOLITE; CAPECITABINE; DOCETAXEL; GEMCITABINE; TAXANE DERIVATIVE;

ABDOMINAL PAIN; ARTICLE; ASPIRATION PNEUMONIA; ASTHENIA; BLOOD TOXICITY; BREAST CANCER; CANCER SURVIVAL; CLINICAL TRIAL; DEPRESSION; DIARRHEA; DISEASE COURSE; DIZZINESS; DRUG DOSE REGIMEN; DRUG EFFICACY; DRUG ERUPTION; DRUG FATALITY; DRUG RESPONSE; DRUG TOLERABILITY; DRUG WITHDRAWAL; DYSPNEA; EDEMA; EUROPE; FATIGUE; FEBRILE NEUTROPENIA; FREQUENCY ANALYSIS; GASTROINTESTINAL TOXICITY; HAND FOOT SYNDROME; HUMAN; INCIDENCE; LEUKOPENIA; LIVER DYSFUNCTION; LUNG DISEASE; LYMPHEDEMA; MEDICAL DECISION MAKING; METASTASIS; MUCOSA INFLAMMATION; MYALGIA; NAIL DISEASE; NAUSEA; NEUROTOXICITY; NEUTROPENIA; PARALYTIC ILEUS; PERIPHERAL NEUROPATHY; RANDOMIZATION; RECALL; RISK BENEFIT ANALYSIS; SIDE EFFECT; TREATMENT FAILURE; TREATMENT PLANNING; VOMITING;

EID: 28944442712     PISSN: 03057372     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0305-7372(05)80004-0     Document Type: Article

References (16)

1. (Abstract 581) Chan S et al. Gemcitabine plus docetaxel (GD) versus capecitabine plus docetaxel (CD) for anythracycline pretreated metastatic breast cancer (MBC) patients (pts): Results of a European Phase III study Proc Am Soc Clin Oncol 2005
2. Blum JL Jones SE Buzdar AU et al. A multicenter phase II study of capecitabine in paclitaxel-refractory metastatic breast cancer J Clin Oncol 17 1999 485-493
3. Carmichael J Possinger K Phillip P et al. Advanced breast cancer: A phase II trial of gemcitabine J Clin Oncol 13 1995 2731-2736
4. Abstract A663 Spielman M Kalla S Llambart-Cussac A et al. Activity of gemcitabine in metastatic breast cancer (MBC) patients previously treated with anthracycline-containing regimens Eur J Cancer 33 Suppl 8 1997
5. Ravdin P Erban J Overmoyer B et al. Phase III comparison of docetaxel and paclitaxel in patients with metastatic breast cancer Proceedings from the 12th European Conference on Clinical Oncology Sept 21-25 2003 Copenhagen, Denmark (Abstract 670)
6. Jones S Erban J Overmoyer B et al. Breast Cancer Research and Treatment, 82: Special Issue: 26th Annual San Antonio Breast Cancer Symposium 2003 Abstract 10
7. Fountzilas G. Nicolaides C. Bafaloukos D. et al. Docetaxel and gemcitabine in anthracycline-resistant advanced breast cancer: A Hellenic Cooperative Oncology Group Phase II study Cancer Invest 18 6 2000 503-509
8. Mavroudis D Malamos N Alexopoulos A et al. Salvage chemotherapy in anthracycline-pretreated metastatic breast cancer patients with docetaxel and gemcitabine: A multicentre phase II trial. Greek Breast Cancer Cooperative Group Ann Oncol 10 2 1999 211-215
9. Abstract 1956 Brandi M. Giotta F. Vici P. et al. Salvage chemotherapy with docetaxel (TXT) and gemcitabine (GEM) in metastatic breast cancer (MBC): Preliminary results of a multicenter phase II trial of GOIM Proc Am Soc Clin Oncol 2001
10. Laufman LR Spiridonidis CH Pritchard J et al. Monthly docetaxel and weekly gemcitabine in metastatic breast cancer: A phase II trial Ann Oncol 12 9 2001 1259-1264
11. Lenz F. Beldermann F. Geberth M. et al. A phase II study of first-line combination chemotherapy with docetaxel and gemcitabine in anthracycline-pretreated HER-2 negative metastatic breast cancer Eur J Cancer Suppl 1 5 2003 S139
12. Kornek GV Haider K Kwasny W et al. Treatment of advanced breast cancer with docetaxel and gemcitabine with and without human granulocyte colony-stimulating factor Clin Cancer Res 8 2003 1051-1056
13. Mavroudis D. Malamos N. Polysos A et al. Front-line chemotherapy with docetaxel and gemcitabine every two weeks in patients with metastatic breast cancer: A multi-center phase II study Oncology 67 3-4 2004 250-256
14. Abstract 201 Garle P.A Calvo L Mayordomo I et al. Gemcitabine and docetaxel given every other week as first-line therapy for metastatic breast cancer (MBC): Final results of a phase II study conducted within the Breast Cancer Investigaton Spanish Group (GEICAM) Proc Am Soc Clin Oncol 2003
15. Albain KS Nag S Calderillo-Ruiz G et al. Global phase III study of gemcitabine plus paclitaxel (GT) vs. paclitaxel (T) as frontline therapy for metastatic breast cancer (MBC): First report of overall survival J Clin Oncol 2004; ASCO Annual Meeting Proceedings (Post-Meeting Edition) 22 2004 15 (14S, July 15 Suppl)
16. O'Shaughnessy J Miles D Vukelja S et al. Superior survival with capecitabine plus docetaxel combination therapy in anthracycline-pretreated patients with advanced breast cancer: Phase II trial results J Clin Oncol 12 2002 2812-2823